Our previously published study showed promising results of autologous stem cell transplantation (ASCT) in patients with primary resistant Hodgkin's disease (HD). Probabilities of overall survival (OS) and progression-free survival (PFS) at 3 years were 55 and 36%, respectively. The present study was undertaken to compare these results with conventionally treated patients and thus evaluate therapeutic options. Retrospective data on 76 adult patients who underwent ASCT were matched with 76 conventionally treated patients from 17 centers. Comparison of clinical characteristics in both groups showed that ASCT patients were younger (24 vs 31.5 years, P ¼ 0.001), more frequently presented with 'B' symptoms (P ¼ 0.03) and that more patients treated with chemotherapy (CT) had elevated LDH (P ¼ 0.03). In univariate analyses, bulky disease (P ¼ 0.0043) and complete resistance to standard CT (P ¼ 0.051) were found to be risk factors for OS. In a multivariate survival analysis only bulky disease was found to an independent prognostic factor (P ¼ 0.005). There was no difference in survival between the treatment groups with 5 years OS 33.7 (CI: 23-46) in the ASCT group and 35.6% (CI: 25-50) for the CT group (P ¼ 0.92). We conclude that ASCT is not superior to standard CT for treatment of patients with primary refractory HD.
dose chemotherapy; autologous stem cell transplantation Identifying the optimum therapy for treatment of primary refractory Hodgkin's disease (HD) is difficult. Use of autologous stem cell transplantation (ASCT) as a treatment modality has proven clinical effectiveness. High-dose chemotherapy (CT) offers 35-60% overall survival (OS) at 5 years, but actual treatment benefit may be overestimated due to selection bias. [1] [2] [3] [4] Randomized trials comparing these two treatments have not been performed to date. A few comparative studies with conventional treatments have been carried out; however, results are equivocal. 5, 6 Our previous study showed promising results of ASCT in patients with primary resistant HD with 3-year OS and progression-free survival (PFS) of 55 and 36%, respectively. The current study was undertaken to compare these results with those from conventionally treated patients. 7 
Patients and methods
Clinical data were collected retrospectively from 17 hematology/oncology centers. Disease status was assessed using the International Prognostic Factors score for advanced HD. Patients with localized disease with risk factors usually received four cycles of CT and extended or involved field radiotherapy. Patients with advanced disease received six cycles of CT sometimes followed by radiotherapy to residual bulky disease. Bulky disease was defined as presence of a nodal mass 45 cm or widening of the madiastinum by more than one-third. Patients were eligible for inclusion in this study if they exhibited disease stabilization or progression during first-line CT, or complete or partial remission after induction treatment, with progression within 3 months after completion of treatment. Patients who did not attain even a partial remission after standard treatment were defined as fully resistant to standard CT. Patients with persistent radiological abnormalities without local progression or residual disease at other sites were not considered to have primary resistance. All transplants were performed between 1990 and May 2002. Nontransplant patients were treated during the same time period as the transplant patients, and only patients treated after 1990 were included in the study.
First-line treatment in the transplant group included ABVD (42%), MOPP(COPP)/ABV (26%), MOPP or COPP (26%), radiotherapy (1%) or other regimens (5%), while in the CT group, 45% of patients received MOPP, 40% -MOPP/ABV, 14% -ABVD and 1% radiotherapy. Second-line treatments in the transplant group included: ABVD (23%), DHAP (16%), LTPAB (12%), EVA (10%), MOPP(COPP)/ABV(7%), DexaBEAM (5%) and other regimens (18%) or radiotherapy (9%). In the CT group, second-line treatments were ABVD (16%), LTPB (14%), dexaBEAM (10%), DHAP (10%), EVA (10%), other regimens (32%) and radiotherapy (8%). The median number of previous CT lines was 2 (range 1-6) in the transplant group and 2 (1-10) in CT group. No grafts were manipulated in vitro. Details of the ASCT patients and their CT matches are summarized in Tables 1 and 2 . Clinical data were collected as of December 2002. Response to therapy was assessed 1 month after completion of treatment. Physical examination, plain X-ray and computed tomography scans were routinely used for response evaluation. Gallium scintigraphy and magnetic resonance imaging were used in selected cases. Definition of disease progression was 25% or more increase from the nadir of the greatest diameter of any previous identified abnormal node for partial responders or nonresponders, or appearance of any new lesion during or less than 90 days after the end of therapy. Biopsy at the time of disease progression was recommended but not obligatory. The complete remission group also included patients with persistent scan abnormalities without biopsy confirmation (complete remission uncertain). Nine of the transplanted patients received interferon alfa and one patient interleukin2 with interferon alfa according to the active local protocol. Patients were included in the study because univariate and multivariate analyses have not confirmed the influence of the immunotherapy on OS and disease-free survival (DFS).
Methods -statistics
Comparisons between factors for the two treatment groups were made using w 2 analyses for categorical data, and a t-test for continuous data. Probabilities of survival and PFS were calculated by the method of Kaplan-Meier. DFS was calculated from the time of achieving complete remission. Survival curves were compared using the log-rank test. Factors found to be significant at the Po0.20 level were then included in a multivariate analysis. In order to determine the significance of treatment on survival, a proportional hazards regression analysis was carried out which included the treatment group adjusted for other prognostic factors. All P-values are two sided. Confidence intervals refer to 95% boundaries.
Results
In the ASCT group, 53 patients (70%) responded to treatment, including 31 (41%) attaining CR and 22 (29%) PR. The median time to reach 0.5 Â 10 4 /ml granulocytes was 12 days (range, 5-70 days), and 1.0 Â 10 4 /ml leukocytes 13 days (range, 6-73 days) and 20 Â 10 4 /ml platelets was 14 days (range, 0-90 days). Seven patients (9%) died from transplant-related causes: six patients died of infections in the early post transplant period, and one death was the result of fatal interstitial pneumonitis 6 months after ASCT. In all, 31 patients (41%) died as a result of HD progression. No cases of myelodysplastic syndrome or secondary malignancy were reported. Probability of survival at 5 years was 33.7% (CI: 23-46). DFS at 3 years for patients achieving a complete response (CR) was 61.1% (CI: 43-77).
In the CT group, 48 (63%) patients responded to salvage treatment: 25 partial response (PR) (33%) and 23 CR (30%). In total, 37 patients (49%) died as a result of disease progression. The 5-year survival probability was 35.6.2% (CI: 23-50). 
Matched analysis
The comparison of clinical characteristics in both groups showed that ASCT patients were younger (24 vs 31.5 years, P ¼ 0.001) more often had 'B' symptoms (P ¼ 0.03), and LDH values (P ¼ 0.03) within normal limits, when compared with the CT group. There was no statistical difference between any of the other factors (Table 1) . On univariate analysis bulky disease (P ¼ 0.0043) and full resistance to standard CT (P ¼ 0.051) were found to be risk factors for OS (Table 3 ). In the multivariate survival analysis, there was no apparent effect of treatment (ASCT vs prognostic factor (P ¼ 0.005) ( Figure 1 , Table 4 ).
Discussion
The outcome of patients with early treatment failure who receive standard-dose salvage CT is invariably poor.
8,9
Recently, encouraging reports on high-dose CT in this group have been published by some institutions, national, and international registries. [1] [2] [3] [4] [5] [6] [7] However, the actual treatment benefit can be overestimated due to selection bias. Jostings et al 4 showed that the majority of primary resistant patients receiving salvage therapy were excluded from high-dose therapy, and only 34% of patients reported in the database of the German Hodgkin's Lymphoma Study Group (GHLSG) received ASCT. Groupe d'Etudes des Lymphomes de l'Adulte (GELA) reported results of the H89 trial, which prospectively accrued patients who had failed to respond completely or relapsed after initial treatment. 10 The MINE (Ifosfamide, Mitoxantrone and Etoposide) salvage therapy and ASCT were integral parts of the protocol. The final analysis revealed that only 32% of patients received the planned treatment without subsequent modifications, and 62% were treated with ASCT. These findings indicate that promising results can be obtained with ASCT by careful selection of patients. Unfortunately, there are no randomized clinical evaluating high-dose CT in this group of patients. Thus, the benefit for ASCT may be only approximated by matching with historical controls.
In our study, we found no differences in favor of highdose treatment. In the Stanford study, there were only 13 patients with induction failure treated with ASCT. In comparison with standard treatment there was no difference in OS at 4 years but the advantage of the high-dosetreatment group was evident in probability of freedom Primary refractory HD: a comparison of ASCT with chemotherapy J Czyz et al from progression (FFP, 52 vs 19%, P ¼ 0.01) and event-free survival (EFS, 52 vs 19%, P ¼ 0.01). In the French study, the 6-year OS from diagnosis was 38% for grafted patients and 29% for patients treated conventionally (P ¼ 0.058). Lack of superiority of ASCT over standard treatment does not rule out the possibility of using this treatment modality in groups of patients selected on the basis of established risk factors. The GHLSG retrospectively analyzed data on 206 patients with primary progressive disease treated with standard CT, ASCT or radiotherapy. Three factors were identified as significant for survival: Karnofsky performance score at progression, age, and attainment of temporary remission to first-line chemotherapy. 4 There are several factors shown in previous studies considered to be of prognostic relevance for OS after ASCT: disease status after salvage CT, 'B' symptoms at the time of progression, failure to achieve even temporary remission after first-line treatment, low Karnofsky performance score at the time of progression or ASCT, age above 50 years and the time interval between diagnosis and ASCT. [2] [3] [4] 6, 7, 11 Retrospective analyses also revealed that bulky and nonresponsive disease had a significant negative influence on post transplant survival.
11 -15 Our results confirm the importance of these factors. Based on our results, we suggest that ASCT should be offered to patients with nonbulky disease who are responding to CT. For patients fully resistant to CT, new options of experimental therapy such as hematopoietic cell transplantation with reduced intensity conditioning, or the best palliative care should be considered. 
